Business Wire

GA-INVERIS-TRAINING-SOLU

Share
InVeris Training Solutions Unveils SRCE™ – a Revolutionary, Augmented Reality Training System

InVeris Training Solutions, the leading provider of integrated live-fire and virtual weapons training systems for military, law enforcement agencies and commercial shooting ranges, today unveils SRCE™ (See, Rehearse, Collectively Experience or "Source"), a groundbreaking, augmented reality-based, untethered weapons training simulator. InVeris Training Solutions provides the most advanced augmented reality technology available in a military and law enforcement training simulator, a feat previously thought to be years away by many in the industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211129005628/en/

"Augmented reality delivers the best of the virtual and real worlds in a way that's fully lifelike, seamless, customizable and economical," said InVeris CEO Al Weggeman. "Physical training facilities can be scanned and augmented to become instant shoot houses by integrating outside content in just minutes. More importantly, we can compare and measure individual and team performance with high precision real-time location tracking of every participant, weapon and even ammunition round."

Critical, use-of-force training can now occur at the point of need or anywhere in the world. This never-experienced complete immersive technology delivers a way to see, rehearse and collectively experience techniques, tactics and procedures with real-time location, movement, orientation and biometric sensing for training and operations. SRCE's proprietary scanning technology allows an instructor to capture the space intended for use as a shoot house using a tablet or other device with a high-resolution camera. Hostile forces, suspects, decoys, hostages, and other parties are all delivered digitally, eliminating the need for opposition role players. SRCE's ability to create a virtual shoot house on the fly lends to active shooter and mission rehearsal training. Wearable, untethered technology, including an AR head-mounted display, provides realistic immersion without compromising freedom of movement and is fully compatible with InVeris' highly accurate BlueFire® simulated weapons.

The unparalleled interactive after-action review (AAR) collects performance data for statistical analysis of never-before-available parameters, including muzzle direction, weapon discharge, missed rounds, eye tracking and head placement. Body sensors monitor a trainee's heart rate, breathing, gaze and other biological signs in real-time. Trainees can even walk through their previous session, seeing every element played back around them as a visualization to review operational performance. This highly immersive AAR creates the optimal opportunity for instructors to increase training fidelity and retention.

For more information on SRCE, visit https://www.inveristraining.com/srce .

About InVeris Training Solutions

InVeris Training Solutions provides cutting-edge training solutions for militaries, law enforcement agencies and commercial range owners around the world. With its legacy companies, FATS® and Caswell, InVeris Training Solutions has fielded over 15,500 live-fire ranges and 7,500 virtual systems globally during its 95-year history. The company is headquartered in Suwanee, Georgia and partners with clients in the U.S. and around the world from facilities on five continents.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment2.12.2025 14:30:00 CET | Press release

CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer. The partnership draws upon CorriXR’s proprietary CRISPR-based gene editing platform targeting NRF2, InhaTarget’s proprietary formulation platform and strong experience in pulmonary drug development, and Merxin Ltd’s advanced inhalation device technology. Through their combined expertise, they aim to create a patient-friendly inhaled therapy that delivers targeted treatment directly to lung tumors, maximizing efficacy, minimizing systemic side effects, and offering new hope for patients facing one of the world’s deadliest cancers. Innovativ

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 14:00:00 CET | Press release

Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become

AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 14:00:00 CET | Press release

Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will evaluate 160 MBq and 200 MBq doses of ADVC001 using a randomized, multi-dose-response design and adaptive dosing strategies to optimize clinical outcomes across three indications: metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) in pre-chemotherapy and post-177Lu-PSMA radioligand therapy (RLT) settings AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling

Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office2.12.2025 14:00:00 CET | Press release

Establishment of the London office follows Luma AI’s $900 million Series C investment led by HUMAIN - marking the company’s first major step towards international scale with plans to deepen partnerships across the UK, European Union, and Saudi Arabia in the first phase of expansion.Former Monks and WPP executive Jason Day was appointed Head of EMEA to launch Luma AI internationally and drive worldwide growth across creative, advertising, gaming, and entertainment sectors.Luma AI plans to add 200 new jobs in London in 2026. Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/ LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING

Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 13:30:00 CET | Press release

Eventbrite stockholders to receive $4.50 per share in cash Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after cl

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye